Business Wire

LabGenius Appoints Dr. Gino Van Heeke as Chief Scientific Officer

Share

LabGenius, the machine learning (ML)-driven protein engineering company, today announced the appointment of Gino Van Heeke Ph.D. as Chief Scientific Officer (CSO). In this role, Gino will leverage his wealth of drug discovery and development experience to direct LabGenius’ scientific strategy.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211129005436/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Dr. Gino Van Heeke Appointed as LabGenius' CSO (Photo: Business Wire)

“I’m extremely pleased to welcome Gino to the company as CSO,” said Dr. James Field, Founder and CEO of LabGenius. “Gino is an accomplished scientific leader with an impressive track record of successfully advancing drug candidates into pre-clinical and clinical development.”

Gino joins LabGenius from Engitix Therapeutics, where, as CSO, he established a portfolio of projects and initiated the company’s first drug discovery campaign. Before this, Gino was Senior Director, Discovery and Early Development at Ablynx where he led the discovery of NANOBODY ® drug candidates and their transition to clinical development. Prior to his move into biotech, Gino held several senior positions at Novartis Institutes for Biomedical Research over a 22-year tenure, including Executive Director for Biologics.

Speaking about his appointment, Dr. Gino Van Heeke said, “The ML-driven protein engineering platform that the team at LabGenius has expertly built presents a tremendous opportunity to revolutionize the way in which drugs are discovered. With solid foundations in place, I am delighted to join the company and apply my drug discovery knowledge and experience to ensure we use our unique platform in the most effective way possible.”

Dr. Edwin Moses, LabGenius Chairman commented “Gino’s expertise in translational research, coupled with LabGenius’ ML-driven drug discovery platform, is an excellent combination which I believe will further accelerate the company’s successful development.”

– end –

About LabGenius

LabGenius is a leading ML-driven protein engineering company, accelerating the discovery of novel therapeutics through the co-optimization of therapeutically valuable properties. The company’s discovery platform, EVATM , integrates several cutting-edge technologies drawn from the fields of computer science, robotic automation and synthetic biology. Headquartered in London, UK, the LabGenius team includes experts in protein engineering, synthetic biology, software engineering, data science and robotic automation.

For more information, please visit www.labgeni.us, or connect on Twitter, Facebook, and LinkedIn.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For more information, please contact:
Media enquiries:
Communications Lead
Lucy Shaw
press@labgeni.us

Business development:
Chief Operating Officer
Didier Landais
didier.landais@labgeni.us

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Feeling ’22: Mary Kay Inc. Announces Awards, Milestones, and Accomplishments From First Half of the Year28.7.2022 20:02:00 EEST | Press release

Mary Kay Inc. is feeling ’22. Throughout the first half of the year, the iconic global entrepreneurship company has furthered its innovations in skin science, continued its social impact efforts, and garnered several prestigious awards for its business and leadership. It’s a thing of beauty—and the nearly 60-year-old brand is just getting started. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220728005228/en/ Mary Kay logo (Graphic: Mary Kay Inc.) 2022 AWARDS & HIGHLIGHTS 30 total awards for business excellence, social impact and sustainability 10 employer awards recognizing Mary Kay as a great place to work and for operational excellence 7 awards for Mary Kay’s c-suite and senior leadership 17 self-released reports reinforcing Mary Kay’s operational and philanthropic efforts supporting its sustainability commitments for its Enriching Lives Today for a Sustainable Tomorrow strategy 3 mentions in annual reports from social i

Asaf Ashkenazi Named CEO of Verimatrix28.7.2022 19:00:00 EEST | Press release

Regulatory News: Verimatrix (Euronext Paris: VMX) (Paris:VMX), today announced the appointment of Asaf Ashkenazi as Chief Executive Officer effective Monday, August 1st, 2022. Amedeo D’Angelo, Chairman and Chief Executive Officer since 2015, remains Executive Chairman of Verimatrix effective the same day. Asaf Ashkenazi joined Verimatrix in 2018 and currently serves as Chief Operating Officer. He will lead the company’s ongoing business model transformation announced last year that focuses on recurring subscription-based revenue sources and new products. “This evolution and reinforcement of the Verimatrix governance structure aligns well with the company’s needs as we further the progression of our business model,” Amedeo D’Angelo said. “I look forward to working closely with Asaf in his newly expanded role as CEO during this strategic development of Verimatrix.” Previously leading the company’s R&D, product, sales and marketing operations, Asaf Ashkenazi will continue to harness his d

GUESS Heads to Granada for the 2022 Fall/Winter Advertising Campaign28.7.2022 18:00:00 EEST | Press release

The new GUESS Fall-Winter 2022 advertising campaign sees the brand off to explore the history-steeped streets of Granada, Spain. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220728005098/en/ GUESS Heads to Granada for the 2022 Fall/Winter Advertising Campaign (Photo: Business Wire) The FW22 campaign is immortalized through the lens of fashion photographer Tatiana Gerusova, under the guidance of GUESS?, Inc.’s Chief Creative Officer, Paul Marciano. The new campaign features a sizzling lineup: German-born, Polish fashion model Kim Dammer, Serbian model Nina Kostić, Spanish model Lidia Santos, Italian model Mario Ermito, and French model Xavier Grey. GUESS Women The campaign showcases an enticing array of GUESS pieces, highlighting must-have accessories and elevated animal and botanical prints. The collection brings a fresh and youthful breeze of contemporary color and style to grey winter days. Against the alluring continent

Innovaderm Bolsters European Presence With Two Newly-Established Operations Hubs (Spain & Poland)28.7.2022 17:00:00 EEST | Press release

Innovaderm announced today that its strategic European expansion initiative has reached a major milestone with the launch of two key centres of operations in Poland and Spain. Biotechnology and pharmaceutical companies can officially partner with the CRO’s team of experts in Europe to manage clinical trials in psoriasis, acne, atopic dermatitis and other dermatology indications. This includes adherence to stringent regulatory requirements, patient recruitment, site selection, clinical monitoring and protocol writing. “To date, we have successfully completed more than 500 clinical trials at 2,900 sites,” says Dave Selkirk, Innovaderm’s Chief Operating Officer. “The presence of two operations hubs in Europe will allow us to go one step further and accelerate the development of promising therapies that have the potential to transform lives. As we look to the future, our goal is to continue supporting innovation in research and the increasing number of patients with skin conditions worldwi

Echosens Partners with World Hepatitis Alliance on World Hepatitis Day, July 28, Urges Importance of Testing and Treatment28.7.2022 16:07:00 EEST | Press release

Echosens, a high-technology company offering liver diagnostic solutions, establishes its support of World Hepatitis Day (WHD), July 28 by partnering with the World Hepatitis Alliance as a bronze sponsor. The commemoration calls for greater awareness of the 357 million people who live with viral hepatitis but are unaware of it. The campaign’s theme “I can’t wait” highlights the need to accelerate the fight against viral hepatitis and the importance of testing and treatment for the real people who need it. “Echosens recognizes that every 30 seconds, someone in the world dies from a hepatitis-related illness, and we join hands with organizations throughout the world to advance increased vigilance around liver health,” says Dominque Legros, Echosens Group CEO. “It is gratifying to see that this year's theme for World Hepatitis Day aligns with our mission for early detection that can result in more effective intervention, treatment and better outcomes.” Viral hepatitis is an inflammation of

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom